OSCR
Oscar Health, Inc.
OSCR has the edge over STAA overall, supported by lower modeled downside and stronger modeled upside.
STAA
STAAR Surgical Company
STAA's outlook is improving despite an expensive valuation.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STAA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
STAA's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over STAA in the historical PE scenario, which offers more potential upside but is not a forecast.
STAA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 50x | $26.78 | — |
| Cheap | 82x | $0.82 | -97% |
| Fair | 132x | $1.32 | -95% |
| Expensive | 350x | $3.50 | -87% |
| Current | 2,678x | $26.78 | — |
Historical ranges are pointers, not guarantees.
STAA's PE is in its expensive range at 2678x. If earnings grow as analysts expect, today's price would be 50x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over STAA on the outlook, with more favorable profitability expectations.
STAA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for STAA, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STAA on earnings, with more consistent year-over-year improvement.
STAA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.54 | +5306% |
| Q3 2026 | $0.01 | +$1.96 |
| Q2 2026 | $0.08 | +$2.01 |
| Q1 2026 | -$0.42 | +$1.02 |
| Q4 2025 | -$1.62 | -$1.21 |
| Q3 2025 | -$1.95 | -543% |
| Q2 2025 | -$1.93 | -668% |
| Q1 2025 | -$1.44 | -565% |
| Q4 2024 | -$0.41 | -195% |
STAA has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STAA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
STAA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.4M | -12% |
| Q2 2026 | $93.5M | +111% |
| Q1 2026 | $93.5M | +120% |
| Q4 2025 | $57.8M | +18% |
| Q3 2025 | $94.7M | +6.9% |
| Q2 2025 | $44.3M | -55% |
| Q1 2025 | $42.6M | -45% |
| Q4 2024 | $49M | -36% |
STAA's revenue is growing: $83M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.5% | -13 points |
| Q2 2026 | 11% | +78 points |
| Q1 2026 | 8.5% | +143 points |
| Q4 2025 | -40% | +18 points |
| Q3 2025 | 20% | +13 points |
| Q2 2025 | -68% | -80 points |
| Q1 2025 | -135% | -132 points |
| Q4 2024 | -57% | -71 points |
STAA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over STAA on cash flow, with more consistent year-over-year improvement.
STAA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | +1379% |
| Q2 2026 | $19.2M | +$48.2M |
| Q1 2026 | -$22.1M | -$14.9M |
| Q4 2025 | -$5.6M | -$508K |
| Q3 2025 | $1.8M | +$4.2M |
| Q2 2025 | -$29M | -$12.4M |
| Q1 2025 | -$7.2M | -144% |
| Q4 2024 | -$5.1M | -118% |
STAA's free cash flow has turned positive after three years mostly in the red: $18M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STAA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -52K shares |
| 1 year | +1.8% | +900K shares |
| 3 years | +4.2% | +2.1M shares |
| 5 years | +3.7% | +1.9M shares |
| Available history | +9.7% | +4.6M shares |
STAA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | $2M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STAA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -13.9x | Net Cash |
| Q2 2026 | -6.7x | Net Cash |
| Q3 2024 | -5.2x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
| Q1 2023 | -2.3x | Net Cash |
| Q4 2022 | -1.8x | Net Cash |
| Q3 2022 | -2.4x | Net Cash |
| Q2 2022 | -4.2x | Net Cash |
STAA has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STAA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 69.4 | Neutral |
STAA's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over STAA on valuation relative to its sector.
STAA PE vs Healthcare Sector
| Metric | STAA | Sector median | Relative |
|---|---|---|---|
| PE | 2,678x | 26x | 10,260% above |
| PE % | 100 | 29 | 71 pts above |
STAA is trading at 2678x earnings, a 10260% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STAA on trend strength, trading above more of its moving averages.
STAA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.1 | 16% above |
| 20 week MA | $23.9 | 12% above |
| 50 week MA | $23.7 | 13% above |
| 100 week MA | $22.8 | 18% above |
| 200 week MA | $33.3 | 19% below |
STAA has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 19% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STAA on returns for 2026, with the stronger performance.
STAA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.5 | $81.4 | +123% |
| 2021 | $81.4 | $96.3 | +18% |
| 2022 | $96.3 | $48.4 | -50% |
| 2023 | $48.4 | $31.2 | -36% |
| 2024 | $31.2 | $24.2 | -22% |
| 2025 | $24.2 | $23.4 | -3.6% |
| 2026 YTD | $23.4 | $26.8 | +15% |
STAA has finished four years in a row lower, and it's up 15% so far in 2026.